Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization

Author： Sun Shawn X.   Lee Kwan Y.   Bertram Carl T.   Goldstein Jay L.  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.23, Iss.8, 2007-08, pp. : 1859-1866

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Review of the selective COX-2 inhibitors celecoxib and rofecoxib: focus on clinical aspects

By  

Canadian Journal of Emergency Medicine, Vol. 4, Iss. 4, 2002-07 ,pp. : 268-275

Cambridge University Press

Access to resources Recommend Favorite

Selective COX-2 Inhibitors and Risk of Myocardial Infarction

By  

Journal of Vascular Research, Vol. 42, Iss. 4, 2005-07 ,pp. : 312-324

Karger

Access to resources Recommend Favorite

Synthesis of novel pyrazolyl tetrazoles as selective COX-2 inhibitors

By Swetha Kolli   Parameshwar Ravula   Reddy B.   babu V.  

Medicinal Chemistry Research, Vol. 22, Iss. 10, 2013-10 ,pp. : 4886-4892

Springer Publishing Company

Access to resources Recommend Favorite

Implementation of NICE guidance on Cox-II selective inhibitors

By Arnold K.  

Journal of Clinical Excellence, Vol. 4, Iss. 3, 2002-07 ,pp. : 315-317

Radcliffe Press

Access to resources Recommend Favorite

Systematic review with meta‐analysis: the gastrointestinal benefits of COX‐2 selective inhibitors with concomitant use of low‐dose aspirin

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 44, Iss. 8, 2016-10 ,pp. : 785-795

John Wiley & Sons Inc

Access to resources Recommend Favorite